New Multi-Center Study Proves Non-Surgical Treatment Reduces Angina

November 10, 1998

Enhanced External Counterpulsation (EECP), a non-invasive therapy with minimal side effects, is effective in reducing angina in individuals who suffer from coronary artery disease, according to a new study conducted at seven medical centers nationwide, including the University of California San Francisco.

It is estimated that more than 11 million Americans have blockages of the blood vessels of the heart, or coronary artery disease, which causes more deaths, disability and economic loss in Westernized nations than any other group of diseases. Although many patients can be managed with medicines, others require invasive procedures with either balloons, stents or coronary artery bypass graft surgery. Despite significant advances in the medical and surgical management of the disease, many patients still suffer the symptoms of angina -- which often involves pain or diminished capacity for exercise and daily activities.

Though the idea of increasing blood flow to the heart using external pressure is about 30 years old, the study which is being presented today (Nov. 10) at the American Heart Association Scientific Sessions in Dallas, demonstrates for the first time that treatment in its modern form has been proven effective, said UCSF Stanford Health Care cardiologist Tony Chou, MD, UCSF assistant professor of medicine and director of the UCSF Adult Cardiac Catheterization Laboratories. The study is the first completed human trial testing the benefits of EECP.

The study found that patients who underwent EECP treatment, which has been available and FDA approved for a less than four years in the United States, had better exercise tolerance and fewer angina attacks and, therefore, had an improved quality of life compared to those who did not receive full treatment, Chou said. These findings, Chou said, are an important step in making EECP a more widely available option for patients who suffer from angina.

"This treatment is very safe, does not involve surgery and is well tolerated," Chou said. "This is very low risk."

EECP treatments, which are offered at a limited number of medical centers including the UCSF Medical Center, part of UCSF Stanford Health Care, typically involve 35 one-hour sessions over about seven weeks. During treatments, patients lie on a bed wearing large pressure cuffs around their calves, lower thighs and upper thighs. The cuffs are inflated and deflated with pressure, which moves blood from the patients' lower limbs toward the heart and increases blood flow in the affected areas of the heart. The treatments are painless, with side effects limited to occasional skin irritation, Chou said.

Though the theory has yet to be proven, cardiologists believe that the treatment works because the increased flow of blood to the heart stimulates the heart to grow new arteries to bypass those that are obstructed or blocked, Chou said. The results of the study clearly show that EECP offers angina patients relief from their symptoms, often when nothing else does, Chou said.

The study, called the MUST-EECP Trial, tracked the progress of 139 patients age 21 to 81 with documented coronary artery disease. Half of those patients received EECP treatments and half of them received placebo, or sham, treatments. Though patients in both groups increased their ability to exercise after the course of the treatment, only the individuals who actually received EECP treatments were able to exercise longer before they showed signs of reduced blood flow to the heart. Most significantly, individuals in the EECP group reported a decrease in the number of angina events they experienced. Use of nitroglycerin, a drug commonly used to treat angina, also dropped in the EECP group.

The reason members of both groups experienced at least some improvement could be due to a placebo effect, meaning even patients who did not really receive treatment responded positively because they expected to feel better and had continuous, close contact with health care providers. In addition, there are still lingering questions about EECP treatment, such as whether it is effective with patients with different forms of angina or when, or if, it should be used as an alternative to other forms of treatment.

The finding that patients who had EECP treatments actually experienced a reduction in their angina means that the therapy is a promising option for patients who have not found relief from other procedures or high-risk individuals, such as the elderly or patients with other illnesses, who are not good candidates for surgical treatments, Chou said.

The MUST-EECP Trial was funded by Vasomedical, Inc. of Westbury, N.Y. Other researchers include: Rohit R. Arora, M.D., Columbia-Presbyterian Medical Center, Columbia University; Diwakar Jain, M.D., Yale University School of Medicine; Bruce Fleishman, M.D., Grant/Riverside Methodist Hospitals; Lawrence Crawford, M.D., University of Pittsburgh Medical Center; Thomas McKiernan, M.D., Loyola University Medical Center; Richard Neto, M.D., Beth Israel Deaconess Medical Center (Harvard Medical School).
-end-


University of California - San Francisco

Related Coronary Artery Disease Articles from Brightsurf:

Researchers use multi-ancestry comparison to refine risk factors for coronary artery disease
An international group led by researchers from the RIKEN Center for Integrative Medical Sciences have used a combination of genome-wide association analysis--or GWAS--and a trans-ancestry comparison of different GWAS studies, to come up with a more accurate predictor of coronary artery disease based on genetic factors.

Oral radiography can reveal chronic coronary artery disease
A study found a link between carotid artery calcification observable in radiographs and coronary artery disease as well as several oral infections.

A new strategy to counter insulin damage in coronary artery disease
By studying blood vessel tissue from 674 patients, a research team has discovered how insulin contributes to the dysfunction of blood vessels in atherosclerosis, one of the most common chronic health conditions worldwide.

3D fusion imaging improves coronary artery disease diagnosis
A new technique that combines CT and MRI can bolster coronary artery disease diagnosis and help to define appropriate treatment for patients suffering from the disease, according to a new study.

Associations between vaspin levels and coronary artery disease
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.0565, Lutfu Askin, Okan Tanriverdi, Hakan Tibilli and Serdar Turkmen from the Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey consider associations between vaspin levels and coronary artery disease.

Waist size, not body mass index, may be more predictive of coronary artery disease
For years, women have been told that weight gain could lead to heart disease.

Women with coronary artery wall thickness at risk for heart disease
The thickness of the coronary artery wall as measured by MRI is an independent marker for heart disease in women, according to a new study.

SPIE journal reports advances in use of 3D models in assessing coronary artery disease
In an article published in SPIE's Journal of Medical Imaging (JMI), researchers announce critical advances in the use of 3D-printed coronary phantoms with diagnostic software, further developing a non-invasive diagnostic method for Coronary Artery Disease (CAD) risk assessment.

E-cigarettes linked to heart attacks, coronary artery disease and depression
Concerns about the addictive nature of e-cigarettes -- now used by an estimated 1 out of 20 Americans -- may only be part of the evolving public health story surrounding their use, according to data being presented at the American College of Cardiology's 68th Annual Scientific Session.

Is guideline-recommended therapy for coronary artery disease more likely in Medicare Advantage?
Medicare Advantage is Medicare's managed-care alternative to traditional fee-for-service Medicare.

Read More: Coronary Artery Disease News and Coronary Artery Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.